Blood‐derived product therapies for SARS‐CoV‐2 infection and long COVID
Junzheng Wu, Huichuan Yang, Ding Yu, Xiaoming Yang · 2023
Read Blood‐derived product therapies for SARS‐CoV‐2 infection and long COVID by Junzheng Wu, Huichuan Yang, Ding Yu, Xiaoming Yang (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10651828.txt.
Description
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is capable of large‐scale transmission and has caused the coronavirus disease 2019 (COVID‐19) pandemic. Patients with COVID‐19 may experience persistent long‐term health issues, known as long COVID. Both acute SARS‐CoV‐2 infection and long COVID have resulted in persistent negative impacts on global public health.
Catalog record
| CREATOR | Junzheng Wu, Huichuan Yang, Ding Yu, Xiaoming Yang |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 75 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |